Credit Suisse AG Grows Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Credit Suisse AG lifted its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 29.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 889,699 shares of the company’s stock after purchasing an additional 199,965 shares during the quarter. Credit Suisse AG owned 0.20% of ImmunityBio worth $1,619,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. State Street Corp grew its stake in ImmunityBio by 255.9% in the 3rd quarter. State Street Corp now owns 6,649,331 shares of the company’s stock worth $33,047,000 after buying an additional 4,780,807 shares in the last quarter. Callan Capital LLC purchased a new position in ImmunityBio in the fourth quarter worth $15,109,000. Pictet Asset Management SA increased its stake in ImmunityBio by 186.2% in the first quarter. Pictet Asset Management SA now owns 2,421,900 shares of the company’s stock valued at $4,408,000 after acquiring an additional 1,575,780 shares during the last quarter. Sheets Smith Wealth Management raised its position in ImmunityBio by 642.6% during the fourth quarter. Sheets Smith Wealth Management now owns 1,544,048 shares of the company’s stock valued at $7,828,000 after purchasing an additional 1,336,122 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in ImmunityBio by 93.4% during the second quarter. Millennium Management LLC now owns 1,179,785 shares of the company’s stock worth $4,389,000 after purchasing an additional 569,696 shares during the last quarter. 8.60% of the stock is currently owned by institutional investors.

ImmunityBio Stock Performance

Shares of IBRX opened at $1.46 on Wednesday. ImmunityBio, Inc. has a fifty-two week low of $1.21 and a fifty-two week high of $7.80. The firm has a 50 day moving average price of $2.20 and a 200-day moving average price of $2.40.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.03 million. Equities analysts expect that ImmunityBio, Inc. will post -1.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut ImmunityBio from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $10.00 to $4.00 in a report on Friday, May 12th.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.